Home     About Us     Team     Products     News     Contact     FAQ     Account

Drugs & Biologicals

Blinatumomab (trade name Blincyto, previously known as AMG103 and MT103) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia...Wikipedia

 

 

 

Manufacturer's Website: Blincyto                                                                                                             Average retail cost: $3,726/dose

 

Search Terms: Blincyto, blinatumomab, Philadelphia chromosome-negative, lymphoblastic leukemia

Copyright 2006-2022 Automated Clinical Guidelines, LLC. All rights reserved.